Ramsay Health Care (ASX:RHC) Might Be Having Difficulty Using Its Capital Effectively

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. However, after briefly looking over the numbers, we don't think Ramsay Health Care (ASX:RHC) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

Advertisement

What Is Return On Capital Employed (ROCE)?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. The formula for this calculation on Ramsay Health Care is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.056 = AU$953m ÷ (AU$21b - AU$3.7b) (Based on the trailing twelve months to December 2024).

Therefore, Ramsay Health Care has an ROCE of 5.6%. Even though it's in line with the industry average of 6.4%, it's still a low return by itself.

Check out our latest analysis for Ramsay Health Care

roce
ASX:RHC Return on Capital Employed August 1st 2025

In the above chart we have measured Ramsay Health Care's prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Ramsay Health Care .

How Are Returns Trending?

In terms of Ramsay Health Care's historical ROCE movements, the trend isn't fantastic. Over the last five years, returns on capital have decreased to 5.6% from 8.6% five years ago. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It may take some time before the company starts to see any change in earnings from these investments.

In Conclusion...

In summary, Ramsay Health Care is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Since the stock has declined 34% over the last five years, investors may not be too optimistic on this trend improving either. In any case, the stock doesn't have these traits of a multi-bagger discussed above, so if that's what you're looking for, we think you'd have more luck elsewhere.

On a final note, we found 3 warning signs for Ramsay Health Care (1 is a bit concerning) you should be aware of.

While Ramsay Health Care isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ASX:RHC

Ramsay Health Care

Owns and operates hospitals in Australia and internationally.

Proven track record and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7057.9% undervalued
19 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17044.9% undervalued
40 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
FU
ONTO logo
FundamentalFlow on Onto Innovation ·

Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Fair Value:US$38033.4% undervalued
26 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.4% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative

Updated Narratives

AN
CHEEDING logo
Anthony_Lee on Cheeding Holdings Berhad ·

Cheeding: The Hidden Beneficiary of Malaysia’s Power Grid Expansion

Fair Value:RM 1.242.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FU
KRMN logo
FundamentalFlow on Karman Holdings ·

KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Fair Value:US$105.653.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
NI
FIBK logo
nitram on First Interstate BancSystem ·

Solid, rationally run company will provide consistent results, stable dividend, and moderate growth

Fair Value:US$4011.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.4% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9722.6% undervalued
57 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1933.2% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative